Art Rastinehad, DO, Receives 2026 Castle Connolly Top Doctor Designation for Urologic Care

Structured Digest of the Announcement

Art Rastinehad, DO, has been named a 2026 Castle Connolly Top Doctor, marking his 12th year receiving this recognition. Dr. Rastinehad serves as a professor of urology and radiology, vice chair of urology at Lenox Hill Hospital, and director for prostate cancer at Northwell Health. This announcement highlights his ongoing clinical and research efforts in precision prostate cancer diagnosis and interventional urology. The designation is awarded annually to physicians selected based on nominations from peers and review by the Castle Connolly research team.

Key Digest

10 Essential Facts at a Glance

Art Rastinehad, DO, was named a 2026 Castle Connolly Top Doctor.
This marks the 12th year Dr. Rastinehad has received the Castle Connolly designation.
Dr. Rastinehad serves as the director for prostate cancer at Northwell Health.
His clinical focus includes MRI-targeted biopsy and focal therapy for prostate conditions.
Castle Connolly selects honorees based on peer nominations and internal research.
The selection process evaluates medical education, training, and disciplinary history.
Dr. Rastinehad holds dual fellowship training in urologic oncology and interventional radiology.
He was part of the first team to publish a series on prostate artery embolization in 2006.
He served as a principal investigator for the development of UroNav/Philips MR/US fusion technology.
Dr. Rastinehad is a founding executive board member of the Focal Therapy Society.

What This Means

The recognition of specialized practitioners in fields like urology and interventional radiology highlights the growing emphasis on precision-based diagnostics for prostate conditions. By integrating advanced imaging technologies such as MR/US fusion biopsies with traditional urologic practices, physicians can provide more granular data regarding patient health markers, such as PSA history and localized cancer risks. This focus on data-driven, individualized treatment planning moves away from standardized protocols, potentially altering how clinicians approach the management of benign prostatic hyperplasia and localized prostate cancer in hospital settings.

Furthermore, the reliance on peer-nominated recognition programs like Castle Connolly serves as a mechanism for institutional quality assurance and professional visibility within the medical community. As the healthcare industry continues to prioritize minimally invasive interventions, the fusion of oncology and interventional radiology—as demonstrated by Dr. Rastinehad’s practice—reflects a broader trend toward multidisciplinary care models. These models aim to streamline the patient experience by combining surgical expertise with image-guided therapy. The long-term efficacy of these integrated approaches remains a subject of ongoing clinical study, as practitioners seek to balance therapeutic outcomes with the preservation of patient quality of life. The continued evolution of these diagnostic and treatment methodologies will likely influence future standards of care for men's health across academic and private clinical environments.

Questions Worth Watching

How will the integration of dual-specialty training affect future training requirements for urologic oncologists?
What impact will the continued adoption of MR/US fusion technology have on the standard detection rates for prostate cancer?
In what ways might peer-nominated physician databases influence patient selection of specialists for complex prostate conditions?

Loading briefing details...